Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal phase III trial of AU-011 for Uveal melanoma

Trial Profile

A pivotal phase III trial of AU-011 for Uveal melanoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AU 011 (Primary)
  • Indications Uveal melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Aura Biosciences
  • Most Recent Events

    • 15 Oct 2019 According to an Aura Biosciences media release, novel design of this study presented at at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting, being held October 12-15, 2019 in San Francisco, CA.This study is expected to commence in the second half of 2020.
    • 02 Apr 2019 According to an Arix Bioscience media release, the study is expected to start in H1 2020.
    • 09 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top